Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics


Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has entered into a definitive agreement to divest Sunosi® (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA), to Axsome Therapeutics (Nasdaq: AXSM).

Read More

Next Post

Healthcare Innovations To Watch Out In 2022 & Beyond

Innovations in healthtech will keep evolving in the coming years. The rise in disposable income will increase the demand for high-quality healthcare and last-mile accessibility. The digital adoption index has suggested that the healthcare industry in India is embracing technological innovations at a much faster pace now than ever before. […]